Scientific Opinion on the substantiation of a health claim related to silymarin BIO-C® and increase in production of breast milk after delivery pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Tabs

Article
Panel on Dietetic Products, Nutrition and Allergies
EFSA Journal
EFSA Journal 2010;8(9):1774 [9 pp.].
doi
10.2903/j.efsa.2010.1774
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen
Acknowledgements

The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen for the preparatory work on this scientific opinion.

Contact
Type
Opinion of the Scientific Committee/Scientific Panel
On request from
MILTE ITALIA S.p.A.
Question Number
EFSA-Q-2009-00957
Adopted
10 September 2010
Published in the EFSA Journal
28 September 2010
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Abstract

Following an application from MILTE ITALIA S.p.A. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to silymarin BIO-C® and increase in production of breast milk after delivery. The food constituent silymarin BIO-C®, an extract of milk thistle (Silybum marianum (L.) Gaertn.) seeds, which is the subject of the health claim, is sufficiently characterised. Increase in production of breast milk after delivery might be a beneficial physiological effect. The target population is women who wish to increase breast milk production. The applicant identified five references as being pertinent to the health claim: two human studies (one published and one unpublished) and three animal studies. The unpublished study investigated the absence of silymarin in breast milk of breastfeeding women who received silymarin and the Panel notes that this study did not address relevant endpoints for the claimed effect. The published human study was a placebo-controlled intervention study conducted with silymarin BIO-C® in breastfeeding women. The Panel notes that this study, which investigated the quantitative and qualitative profile of the milk from the women, suffered from several shortcomings and no conclusions could be drawn for the scientific substantiation of the claimed effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of silymarin BIO-C® and increase in production of breast milk after delivery.

Keywords
Silymarin BIO-C®, production of breast milk, health claims.
Print on demand
Number of Pages
9